期刊文献+

药物洗脱支架在防治颅内外支架成形术后再狭窄的作用 被引量:3

The Roles of Drug-Fluting Stents in the Prevention and Treatment of Restenosis After Extracranial and Intracranial Stent Angioplasty
原文传递
导出
摘要 目前,有症状颅内外动脉狭窄支架置入术多使用裸金属支架,但再狭窄发生率较高。药物洗脱支架治疗冠状动脉粥样硬化病变的研究表明,再狭窄发生率显著降低。虽然颅内外动脉狭窄的药物洗脱支架支架置入术也是安全的,但是还需大样本前瞻性随机对照试验证实其安全性和有效性。 Now symptomatic extracranial and intracranial stenting usually uses bare metal stentts, but the incidence of restenosis is higher. The studies of drug-eluting stentts for the treatment of coronary atherosclerosis have suggested that the incidence of restenosis decreases significantly. Although extracranial and intracranial drug-eluting stentt placement appears to be safe, further large, prospective, randomized, controlled trials are needed to demonstrate its safety and effectiveness.
出处 《国际脑血管病杂志》 2007年第10期775-778,共4页 International Journal of Cerebrovascular Diseases
关键词 颅内外动脉狭窄 药物洗脱支架 血管成形术 再狭窄 extracranial and intracranial arterial stenosis drug-eluting stent angioplasty restenosis
  • 相关文献

参考文献32

  • 1Sprague EA. In vivo cardiovascular assays for drug discovery: evolution of the drug-eluting stent. Curr Opin Investig Drugs, 2007, 8:219 - 225.
  • 2Bosiers M, De Donato G, Deloose K, et al. Are there predictive risk factors for complications after carotid artery stenting? J Cardiovasc Surg (Torino), 2007, 48:125 - 130.
  • 3Philippe F,Dibie A,Larrazet F,et al.Drug eluting stents: from evidence based medicine to clinical practice. Ann Cardiol Angeiol (Paris), 2005, 54: 201 -211.
  • 4Garcia-Garcia HM,Vaina S, Tsuchida K, et al. Drug-eluting stems. Arch Cardiol Mex, 2006, 76:297 -319.
  • 5Holmes DR Jr, Teirstein P, Satler L, et al. Sirolimus-eluting stents vs vascular brachytherapy for in-stent restenosis within bare-metal stents: the SISR randomized trial. JAMA, 2006, 295:1264 - 1273.
  • 6Sheiban I, Chiribiri A, Beninati S, et al. Sirolimus-eluting stents for the treatment of bare-metal in-stent restenosis: long-term clinical follow up. J Invasive Cardiol, 2007, 19:174 - 180.
  • 7Moses JW, Nikolsky E, Mehran R, et al. Safety and efficacy of the 2. 25-mm sirolimus-eluting Bx Velocity stent in the treatment of patients with de novo native coronary artery lesions: the SIRIUS 225 trial. Am J Cardiol, 2006, 98:1455 - 1460.
  • 8Dangas G, Ellis SG, Shlofmitz R, et al. Outcomes of paclitaxel-eluting stent implantation in patients with stenosis of the left anterior descending coronary artery. J Am Coil Cardiol, 2005, 45:1186 - 1192.
  • 9Stone GW, Ellis SG, O'Shaughnessy CD, et al. Paclitaxel-eluting stents vs vascular brachytherapy for in-stent restenosis within bare-metal stents: the TAXUS V ISR randomized trial. JAMA, 2006, 295 : 1253 - 1263.
  • 10Dawkins KD,Grube E,Guagliumi G, et al. Clinical efficacy of polymerbased paclitaxel-eluting stents in the treatment of complex, long coronary artery lesions from a multicenter, randomized trial: support for the use of drug-eluting stents in contemporary clinical wactice. Circulation, 2005, 112:3306 -3313.

二级参考文献7

  • 1Moses JW, O′Shaughnessy C, Caputo R, et al. The US multicenter, randomized, double blind study of the sirolimus-eluting stent in coronary lesions: safety outcomes at 9 months. Eur Heart J, 2002,23(Suppl): 264.
  • 2Buergler JM, Tio FO, Schulz DG, et al. Use of nitric-oxide-eluting polymer-coated coronary stents for prevention of restenosis in pigs. Coron Artery Dis,2000,11:351-357.
  • 3Schwartz RS, Huber KC, Murphy JG, et al. Restenosis and the proportional neointimal response to coronary artery injury: results in a porcine model. J Am Coll Cardiol,1992, 19:267-274.
  • 4Morice WG, Brunn GJ, Wiederrecht G,et al. Rapamycin-induced inhibition of p34cdc2 kinase activation is associated with G1/S-phase growth arrest in T lymphocytes. J Biol Chem, 1993,268:3734-3738.
  • 5Klugherz BD,Llanos G,Lieuallen W,et al.Twenty-eight day efficacy and pharmacokinetics of the sirolimus-eluting stent.Coron Artery Dis,2002,13:183-188.
  • 6Tanabe K, Degertekin M, Regar E, et al. No delayed restenosis at 18 months after implantation of sirolimus-eluting stent. Catheter Cardiovasc Intervent, 2002,57:65-68.
  • 7Klugherz BD, Llanos G, Lieuallen W, et al. Twenty-eight-day efficacy and phamacokinetics of the sirolimus-eluting stent. Coron Artery Dis,2002,13:183-188.

共引文献14

同被引文献40

引证文献3

二级引证文献6

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部